Mirum Pharmaceuticals (NASDAQ:MIRM) SVP Jolanda Howe Sells 2,594 Shares

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) SVP Jolanda Howe sold 2,594 shares of the business’s stock in a transaction on Wednesday, June 17th. The shares were sold at an average price of $101.95, for a total transaction of $264,458.30. Following the completion of the transaction, the senior vice president owned 5,835 shares of the company’s stock, valued at approximately $594,878.25. This represents a 30.77% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Mirum Pharmaceuticals Stock Up 5.0%

MIRM stock opened at $107.13 on Friday. The firm has a market cap of $6.53 billion, a PE ratio of -7.87 and a beta of 0.50. The company has a debt-to-equity ratio of 1.28, a quick ratio of 1.99 and a current ratio of 2.09. The firm’s fifty day moving average is $98.51 and its 200 day moving average is $92.12. Mirum Pharmaceuticals, Inc. has a one year low of $47.89 and a one year high of $114.99.

Mirum Pharmaceuticals (NASDAQ:MIRM) last released its quarterly earnings data on Wednesday, May 6th. The company reported ($13.43) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.75) by ($12.68). Mirum Pharmaceuticals had a negative net margin of 140.24% and a negative return on equity of 11.28%. The firm had revenue of $159.88 million during the quarter, compared to analysts’ expectations of $148.21 million. During the same period in the previous year, the firm posted ($0.30) EPS. The firm’s quarterly revenue was up 43.3% on a year-over-year basis. On average, research analysts forecast that Mirum Pharmaceuticals, Inc. will post -2.01 EPS for the current year.

Hedge Funds Weigh In On Mirum Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Cullen Frost Bankers Inc. purchased a new stake in shares of Mirum Pharmaceuticals during the fourth quarter worth approximately $30,000. Eurizon Capital SGR S.p.A. acquired a new position in Mirum Pharmaceuticals in the 4th quarter valued at $32,000. CIBC Private Wealth Group LLC purchased a new position in Mirum Pharmaceuticals in the 4th quarter valued at $32,000. Quantbot Technologies LP purchased a new position in Mirum Pharmaceuticals in the 3rd quarter valued at $33,000. Finally, Comerica Bank boosted its stake in Mirum Pharmaceuticals by 45.1% during the 1st quarter. Comerica Bank now owns 895 shares of the company’s stock worth $40,000 after purchasing an additional 278 shares during the last quarter.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on MIRM. Wall Street Zen downgraded Mirum Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Weiss Ratings upgraded Mirum Pharmaceuticals from a “sell (d-)” rating to a “sell (d)” rating in a research report on Monday, June 8th. Robert W. Baird lifted their price target on shares of Mirum Pharmaceuticals from $112.00 to $129.00 and gave the company an “outperform” rating in a research note on Thursday, May 7th. TD Cowen boosted their price target on shares of Mirum Pharmaceuticals from $125.00 to $145.00 and gave the stock a “buy” rating in a report on Thursday, May 7th. Finally, Citizens Jmp upped their price objective on shares of Mirum Pharmaceuticals from $140.00 to $146.00 and gave the stock a “market outperform” rating in a research report on Monday. One analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Mirum Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $139.80.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.